Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013092 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Eric M Burton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Viral Matrix Proteins, B-Lymphocytes, Herpesvirus 4, Human, IMP Dehydrogenase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) is associated with multiple types of cancers, many of which express the viral oncoprotein Latent Membrane Protein 1 (LMP1). LMP1 contributes to both epithelial and B-cell transformation. Although metabolism reprogramming is a cancer hallmark, much remains to be learned about how LMP1 alters lymphocyte oncometabolism. To gain insights into key B-cell metabolic pathways subverted by LMP1, we performed systematic metabolomic analyses on B cells with conditional LMP1 expression. This approach highlighted that LMP highly induces de novo purine biosynthesis, with xanthosine-5-P (XMP) as one of the most highly LMP1-upregulated metabolites. Consequently, IMPDH inhibition by mycophenolic acid (MPA) triggered death of LMP1-expressing EBV-transformed lymphoblastoid cell lines (LCL), a key model for EBV-driven immunoblastic lymphomas. Whereas MPA instead caused growth arrest of Burkitt lymphoma cells with the EBV latency I program, conditional LMP1 expression triggered their death, and this phenotype was rescuable by guanosine triphosphate (GTP) supplementation, implicating LMP1 as a key driver of B-cell GTP biosynthesis. Although both IMPDH isozymes are expressed in LCLs, only IMPDH2 was critical for LCL survival, whereas both contributed to proliferation of Burkitt cells with the EBV latency I program. Both LMP1 C-terminal cytoplasmic tail domains critical for primary human B-cell transformation were important for XMP production, and each contributed to LMP1-driven Burkitt cell sensitivity to MPA. Metabolomic analyses further highlighted roles of NF-kB, mitogen activated kinase, and protein kinase C downstream of LMP1 in support of XMP abundance. Of these, only protein kinase C activity was important for supporting GTP levels in LMP1 expressing Burkitt cells. MPA also de-repressed EBV lytic antigens, including LMP1 itself in latency I Burkitt cells, highlighting crosstalk between the purine biosynthesis pathway and the EBV epigenome. These results suggest novel oncometabolism-based therapeutic approaches to LMP1-driven lymphomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
- Center for Integrated Solutions for Infectious Diseases, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America.
- Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.
- Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
- Harvard Program in Virology, Harvard Medical School, Boston, Massachusetts, United States of America.
ORCID-Profile: Eric M Burton, Benjamin E Gewurz
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIDCR NIH HHS
- American Cancer Society
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Division of Cancer Prevention, National Cancer Institute
- Division of Cancer Epidemiology and Genetics, National Cancer Institute
Zitieren
APA
Burton, E. M., Maestri, D., White, S., Liang, J. H., Mitra, B., Asara, J. M., & Gewurz, B. E. (2025). Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013092
Vancouver
Burton EM, Maestri D, White S, Liang JH, Mitra B, Asara JM, et al. Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013092
BibTeX
@article{Burton2025,
author = {Burton, Eric M and Maestri, Davide and White, Shaowen and Liang, Jin-Hua and Mitra, Bidisha and Asara, John M and Gewurz, Benjamin E},
title = {Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013092}
}
EUVIMED